1. Home
  2. ATI vs BBIO Comparison

ATI vs BBIO Comparison

Compare ATI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATI
  • BBIO
  • Stock Information
  • Founded
  • ATI 1960
  • BBIO 2015
  • Country
  • ATI United States
  • BBIO United States
  • Employees
  • ATI N/A
  • BBIO N/A
  • Industry
  • ATI Steel/Iron Ore
  • BBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATI Industrials
  • BBIO Health Care
  • Exchange
  • ATI Nasdaq
  • BBIO Nasdaq
  • Market Cap
  • ATI 11.2B
  • BBIO 9.4B
  • IPO Year
  • ATI N/A
  • BBIO 2019
  • Fundamental
  • Price
  • ATI $80.34
  • BBIO $54.30
  • Analyst Decision
  • ATI Strong Buy
  • BBIO Strong Buy
  • Analyst Count
  • ATI 7
  • BBIO 16
  • Target Price
  • ATI $99.67
  • BBIO $64.44
  • AVG Volume (30 Days)
  • ATI 1.5M
  • BBIO 1.9M
  • Earning Date
  • ATI 10-28-2025
  • BBIO 11-11-2025
  • Dividend Yield
  • ATI N/A
  • BBIO N/A
  • EPS Growth
  • ATI 9.13
  • BBIO N/A
  • EPS
  • ATI 2.89
  • BBIO N/A
  • Revenue
  • ATI $4,508,700,000.00
  • BBIO $235,812,000.00
  • Revenue This Year
  • ATI $7.10
  • BBIO $115.46
  • Revenue Next Year
  • ATI $7.49
  • BBIO $65.03
  • P/E Ratio
  • ATI $27.75
  • BBIO N/A
  • Revenue Growth
  • ATI 6.64
  • BBIO 7.62
  • 52 Week Low
  • ATI $39.23
  • BBIO $21.72
  • 52 Week High
  • ATI $96.20
  • BBIO $57.49
  • Technical
  • Relative Strength Index (RSI)
  • ATI 49.34
  • BBIO 53.48
  • Support Level
  • ATI $79.29
  • BBIO $52.97
  • Resistance Level
  • ATI $86.32
  • BBIO $57.48
  • Average True Range (ATR)
  • ATI 2.73
  • BBIO 1.69
  • MACD
  • ATI -0.33
  • BBIO -0.09
  • Stochastic Oscillator
  • ATI 19.77
  • BBIO 40.59

About ATI ATI Inc.

ATI Inc supplies specialty metals to various end markets, including aerospace and defense, oil and gas, automotive, and electrical energy, among many others. The company's operating segment includes High-Performance Materials and Components and Advanced Alloys and Solutions. The majority of revenue is from the High-Performance Materials segment. The High-Performance Materials segment is focused on a wide range of high-performance specialty materials, parts, and components for several the majority of end markets, including the aerospace & defense, medical, and energy markets. Geographically, it operates in the United States, China, the United Kingdom, Germany, France, Canada, and Others, the majority is from the United States.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: